Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma

British Journal of Cancer

Volumn 99, Issue 11, 2008, Pages 1891-1899

  Honda, S ^a,d   Arai, Y ^b   Haruta, M ^a   Sasaki, F ^c   Ohira, M ^c   Yamaoka, H ^c   Horie, H ^c   Nakagawara, A ^c   Hiyama, E ^c   Todo, S ^d   Kaneko, Y ^a,c  

^a SAITAMA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c Japanese Study Group for Pediatric Liver Tumor (JPLT)   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

H19; Hepatoblastoma; IGF2; Loss of heterozygosity; Loss of imprinting

Indexed keywords

RNA H19; SOMATOMEDIN B;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBRYO DEVELOPMENT; FEMALE; FETUS LIVER; GENE EXPRESSION; GENE FREQUENCY; GENE LOSS; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HEPATOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; BETA CATENIN; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA-BINDING PROTEINS; GENOMIC IMPRINTING; HEPATOBLASTOMA; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 56749160042     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604754     Document Type: Article

References (43)

1. Albrecht S, Hartmann W, Houshdaran F, Koch A, Gärtner B, Prawitt D, Zabel BU, Russo P, Von Schweinitz D, Pietsch T (2004) Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma. Int J Cancer 111: 627-632
2. Beeghly AC, Katsaros D, Wiley AL, Rigault de la Longrais IA, Prescott AT, Chen H, Puopolo M, Rutherford TJ, Yu H (2007) IGF-II promoter methylation and ovarian cancer prognosis. J Cancer Res Clin Oncol 133: 713-723
3. Bell AC, Felsenfeld G (2000) Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405: 482-485
4. Davies SM (1993) Maintenance of genomic imprinting at the IGF2 locus in hepatoblastoma. Cancer Res 53: 4781-4783
5. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB (2005) Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205: 145-153
6. Fuchs J, Rydzynski J, Von Schweinitz D, Bode U, Hecker H, Weinel P, Bürger D, Harms D, Erttmann R, Oldhafer K, Mildenberger H (2002) Pretreatment prognostic factors and treatment results in children with hepatoblastoma. Cancer 95: 172-182
7. Fukuzawa R, Breslow NE, Morison IM, Dwyer P, Kusafuka T, Kobayashi Y, Becroft DM, Beckwith JB, Perlman EJ, Reeve AE (2004) Epigenetic differences between Wilms' tumours in white and East-Asian children. Lancet 363: 446-451
8. Fukuzawa R, Umezawa A, Ochi K, Urano F, Ikeda H, Hata J (1999) High frequency of inactivation of the imprinted H19 gene in 'sporadic' hepatoblastoma. Int J Cancer 82: 490-497
9. Gray SG, Eriksson T, Ekström C, Holm S, von Schweinitz D, Kogner P, Sandstedt B, Pietsch T, Ekström TJ (2000) Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 82: 1561-1567
10. Grundy P, Telzerow P, Moksness J, Breslow NE (1996) Clinicopathologic correlates of loss of heterozygosity in Wilms' tumors: a preliminary analysis. Med Pediatr Oncol 27: 429-433
11. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM (2000) CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405: 486-489
12. KIP2, IGF2, and H19. Am J Pathol 157: 1393-1403
13. Haruta M, Arai Y, Sugawara W, Watanabe N, Honda S, Ohshima J, Soejima H, Nakadate H, Okita H, Hata J, Fukuzawa M, Kaneko Y (2008) Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 47: 712-727
14. Hedborg F, Holmgren L, Sandstedt B, Ohlsson R (1994) The cell type-specific IGF2 expression during early human development correlates to the pattern of overgrowth and neoplasia in the Beckwith-Wiedemann syndrome. Am J Pathol 145: 802-817
15. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826
16. Honda S, Haruta M, Sugawara W, Sasaki F, Ohira M, Matsunaga T, Yamaoka H, Horie H, Ohnuma N, Nakagawara A, Hiyama E, Todo S, Kaneko Y (2008) The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 123: 1117-1125
17. Koch A, Denkhaus D, Albrecht S, Leuschner I, Von Schweinitz D, Pietsch T (1999) Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 59: 269-273
18. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekström TJ (1995) Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 11: 221-229
19. Li X, Gray SG, Flam F, Pietsch T, Ekström TJ (1998a) Developmental-dependent DNA methylation of the IGF2 and H19 promoters is correlated to the promoter activities in human liver development. Int J Dev Biol 42: 687-693
20. Li X, Kogner P, Sandstedt B, Haas OA, Ekström TJ (1998b) Promoter-specific methylation and expression alterations of igf2 and h19 are involved in human hepatoblastoma. Int J Cancer 75: 176-180
21. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Schwartz P, Yu H (2006) Promoter-specific transcription of insulin-like growth factor II in epithelial ovarian cancer. Gynecol Oncol 103: 990-995
22. Maiti S, Alam R, Amos CI, Huff V (2000) Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res 60: 6288-6292
23. Matsunaga T, Sasaki F, Ohira M, Hashizume K, Hayashi A, Hayashi Y, Matsuyama K, Mugishima H, Ohnuma N (2004) The role of surgery in the multimodal treatment for hepatoblastomas. Shounigan 41: 205-210 (in Japanese)
24. Montagna M, Menin C, Chieco-Bianchi L, D'Andrea E (1994) Occasional loss of constitutive heterozygosity at 11p15.5 and imprinting relaxation of the IGFII maternal allele in hepatoblastoma. J Cancer Res Clin Oncol 120: 732-736
25. Perilongo G, Shafford EA (1999) Liver tumours. Eur J Cancer 35: 953-958
26. Perilongo G, Shafford S, Plaschkes J (2000) SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 1: 94-100
27. Rainier S, Dobry CJ, Feinberg AP (1995) Loss of imprinting in hepatoblastoma. Cancer Res 55: 1836-1838
28. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg AP (2001) Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 93: 1698-1703
29. Ross JA, Radloff GA, Davies SM (2000) H19 and IGF-2 allele-specific expression in hepatoblastoma. Br J Cancer 82: 753-756
30. Ryan PD, Goss PE (2008) The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13: 16-24
31. Satoh Y, Nakagawachi T, Nakadate H, Kaneko Y, Masaki Z, Mukai T, Soejima H (2003) Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor. J Biochem 133: 303-308
32. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP (1994) Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms tumor. Nat Genet 7: 433-439
33. Sugawara W, Haruta M, Sasaki F, Watanabe N, Tsunematsu Y, Kikuta A, Kaneko Y (2007) Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 49: 240-249
34. Suzuki M, Kato M, Yuyan C, Takita J, Sanada M, Nannya Y, Yamamoto G, Takahashi A, Ikeda H, Kuwano H, Ogawa S, Hayashi Y (2008) Whole-genome profiling of chromosomal aberrations in hepatoblastoma using high-density single-nucleotide polymorphism genotyping microarrays. Cancer Sci 99: 564-570
35. Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA (2001) Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 10: 2619-2626
36. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W (2002) Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21: 4863-4871
37. Toretsky JA, Helman LJ (1996) Involvement of IGF-II in human cancer. J Endocrinol 149: 367-372
38. Vu TH, Hoffman AR (1999) Alterations in the promoter-specific imprinting of insulin-like growth factor-II gene in Wilms tumor. J Biol Chem 271: 9014-9023
39. Wang WH, Duan JX, Vu TH, Hoffman AR (1996) Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity. J Biol Chem 271: 27863-27870
40. Watanabe N, Haruta M, Soejima H, Fukushi D, Yokomori K, Nakadate H, Okita H, Hata J, Fukuzawa M, Kaneko Y (2007) Duplication of the paternal IGF2 allele in trisomy 11 and elevated expression levels of IGF2 mRNA in congenital mesoblastic nephroma of the cellular or mixed type. Genes Chromosomes Cancer 46: 929-935
41. Watanabe N, Nakadate H, Haruta M, Sugawara W, Sasaki F, Tsunematsu Y, Kikuta A, Fukuzawa M, Okita H, Hata J, Soejima H, Kaneko Y (2006) Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 45: 592-601
42. Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B (2005) Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 3: 493-502
43. Zatkova A, Rouillard JM, Hartmann W, Lamb BJ, Kuick R, Eckart M, von Schweinitz D, Koch A, Fonatsch C, Pietsch T, Hanash SM, Wimmer K (2004) Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 39: 126-137